Study Pharmacokinetic and Pharmacodynamic Outcomes of Tocilizumab Treatment in Giant Cell Arteritis after Subcutaneous and Intravenous Dosing
Latest Information Update: 19 Nov 2018
Price :
$35 *
At a glance
- Drugs Tocilizumab (Primary) ; Tocilizumab (Primary)
- Indications Giant cell arteritis
- Focus Pharmacodynamics; Pharmacokinetics; Therapeutic Use
- 19 Nov 2018 New trial record
- 24 Oct 2018 Results presented at the 82nd American College of Rheumatology and the 52nd Association of Rheumatology Health Professionals Annual Scientific Meeting